Plureon’s platform technology is a pluripotent stem cell which can be isolated harmlessly at birth from placental tissue which is otherwise usually discarded as medical waste.

These stem cells (“Plureon Stem Cells” or “PSCs”) have been differentiated into cells of all three germ layers, including bone, skeletal muscle, cardiac muscle, liver, nerve, fat, and pancreatic cells.

PSCs have also demonstrated efficacy in several disease models.

A key feature of PSCs is their proliferative potential. PSC populations double approximately every 36 hours. They are stable in culture; their key properties do not change even after hundreds of population doublings. This proliferative quality is crucial in the development of therapeutic applications, where billions of cells may be needed for a single tissue reconstruction or cell therapy application.

Unlike human embryonic stem (“hES”) cells which form teratomas when implanted in vivo, PSCs are not cancer-forming. Also, PSCs are obtained without harm to an embryo or fetus.

PSCs have a potentially wide range of therapeutic application. Plureon is pursuing these both internally and in conjunction with corporate partners.